Alzheimer's Disease

 The effectiveness of these medications appears to be modest but significant for a large number of patients who can tolerate their side effects. On average, the cognitive enhancers slow down for six months or more the encroachment of Alzheimer's disease on multiple areas of functioning. "This study is important because it demonstrates that although milder therapeutic drugs (such as riluzole) have been shown in animal models and are currently being tested by doctors treating several different types Parkinsonian disorders, they don't eliminate both neurodegenerative symptoms and impairments in normal memory," says Dr Wollenbergs. He adds: I believe this paper will help us further understand how the medication works with cognition impairment.  So the drug is effective for a fixed time or months. 

 The U.S. Food and Drug Administration (FDA) has approved two types of medications — cholinesterase inhibitors (Aricept®, Exelon®, Razadyne®) and memantine (Namenda®) — to treat the cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning) of Alzheimer's disease. Cholamines are compounds that activate brain receptors for excitatory neurotransmitters called monoamine oxidases (MAO). The drug in question is a class C MAOA inhibitor named rapamycin is known as "prilosec." In humans this inhibits enzyme activity within nerve cells located on both hemispheres where different pathways exist between these parts at synapses which can cause long-term behavioral changes such: behavior disorders, impulsivity/impulsive thoughts associated behaviors or aggression. These disruptions result from impairment by impaired functioning of each single neuromodulatory pathway involved when those particular neurons produce dopamine – an important signal needed. To tre